Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-39324 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AL-39324 Concentration Level A | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level B | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level C | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level D | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| AL-39324 Concentration Level E | EXPERIMENTAL | AL-39324 ophthalmic suspension, single intravitreal injection |
| Lucentis | ACTIVE_COMPARATOR | Ranibizumab 10 mg/mL solution, single intravitreal injection |
| Name | Type | Description |
|---|---|---|
| AL-39324 ophthalmic suspension | DRUG | - |
| Ranibizumab 10 mg/mL | DRUG | - |
Inclusion Criteria: * Willing to give written informed consent, make the required study visits and follow instructions; * The study eye: * must have a primary diagnosis of choroidal neovascularization (CNV) secondary to AMD; * lesion must be no larger than 30 mm2; * must have edema measuring...
AL-39324 is an investigational small molecule being developed for the treatment of Age Related Macular Degeneration (AMD). It is being studied in the ophthalmology therapeutic area. The drug is currently in Phase 2 clinical development and is not yet approved for any use.
AL-39324 is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is conducting clinical research on this investigational drug for the treatment of Age Related Macular Degeneration.
AL-39324 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Age Related Macular Degeneration, and its Phase 2 trial has been completed.
AL-39324 has one completed Phase 2 clinical trial registered under the identifier NCT00992563. The trial, titled WALTZ, was a randomized, double-blind, active-controlled study that enrolled 35 participants aged 50 years and older with Age Related Macular Degeneration.
No, AL-39324 is the drug being studied, while WALTZ is the name of the clinical trial. The WALTZ trial, with the identifier NCT00992563, was a Phase 2 study evaluating AL-39324 in patients with Age Related Macular Degeneration. The trial has been completed.